TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05808634: Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

Sponsor: BioAtla, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 168 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT05808634 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05808634 Rescue Dossier →